Please try another search
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Name | Age | Since | Title |
---|---|---|---|
Tomoyoshi Soga | - | 2003 | Co-Founder and Member of Technical Advisory Board |
Masaru Tomita | - | 2003 | Co-Founder and Member of Technical Advisory Board |
Katsuhito Hashizume | 54 | - | President, CEO & Director |
Toshio Nagae | 79 | 2017 | Independent Director |
Hajime Natsukari | - | 2022 | Independent Director |
Yasuhiro Ohata | 58 | - | Director of Corporate Headquarters & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review